Search results for "Renal Cell"

showing 10 items of 231 documents

Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer.

1998

Although not structurally related, the pleiotropic cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15) share a variety of biological functions including stimulation and maintenance of cellular immune responses. Cytokines, such as IL-7 or IL-15, elaborated by cells in situ, e.g. cancer cells, may be involved in shaping the quality of anti-tumor directed immune responses. We have analysed the constitutive and IFN-gamma-inducible expression of IL-15 or IL-7 mRNA, protein expression, and protein secretion in human tumor cell lines of distinct origin. IL-15 mRNA expression was detected in renal cell carcinoma (RCC), small cell lung carcinoma (SCLC), glioblastoma, neuroblastoma, mesotheliom…

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentCellBiologyInterferon-gammaInternal medicinemedicineHumansSecretionRNA MessengerCarcinoma Renal CellInterleukin-15OncogeneInterleukin-7CancerCell cyclemedicine.diseaseKidney NeoplasmsEndocrinologymedicine.anatomical_structureCytokineOncologyGene Expression RegulationInterleukin 15Cancer cellCancer researchColorectal NeoplasmsInternational journal of oncology
researchProduct

Prognostic role of tumour multifocality in renal cell carcinoma.

2012

Study Type - Therapy (multi-centre cohort) Level of Evidence3b What's known on the subject? and What does the study add? In RCC about 5% of the patients presented multifocal disease. Prevalence of tumour multifocality was associated with a higher percentage of symptomatic RCC, higher pathological TNM stages, higher tumour grade and higher prevalence of tumour necrosis. Although in univariable analysis multifocal tumours had lower probability of CSS, tumour multifocality did not retain an independent predictive role in multivariable analysis. Patient age at surgery, gender, mode of presentation, pathological N stage and presence of metastases were independent predictors of CSS in multivariab…

Cancer-specific survivalMalePrognosiUrologyRenal cell carcinoma; oncology; PrognosisNephrectomyFollow-Up StudieRetrospective StudiePrevalenceHumansCarcinoma Renal CellNeoplasm StagingProportional Hazards ModelsRetrospective StudiesPrognostic factorCancer-specific survival; Multifocality; Prognostic factor; Renal cell carcinomaKidney NeoplasmMultifocalityMiddle AgedPrognosisRenal cell carcinomaKidney NeoplasmsSurvival RateItalyoncologyProportional Hazards ModelFemaleTomography X-Ray ComputedHumanFollow-Up Studies
researchProduct

Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma.

2009

OBJECTIVE To investigate the prognostic relevance of different histopathological features and local tumour extension in patients with pT3b/c N0M0 renal cell carcinoma (RCC), as recently new proposals of reclassifying tumour fat invasion in pT3b/c RCC have been made but the effect of other histopathological tumour characteristics and combinations thereof with tumour invasion has yet to be determined in these patients. PATIENTS AND METHODS Between 1990 and 2006, 1943 patients underwent surgical treatment for renal tumours in our institution, of which 175 patients (8.7%) had pT3b/c RCC. After exclusion of 57 patients (32.6%) with lymph node and/or distant metastases at the time of diagnosis, 1…

Capsular InvasionAdultMalemedicine.medical_specialtyPathologyUrologyGastroenterologyNephrectomyAdipose capsule of kidneyRenal cell carcinomaInternal medicineCarcinomaMedicineHumansRenal sinusLymph nodeCarcinoma Renal CellAgedNeoplasm StagingAged 80 and overUnivariate analysisbusiness.industryMiddle Agedmedicine.diseasePrognosisKidney Neoplasmsmedicine.anatomical_structureTreatment OutcomeAdipose TissueFemalebusinessEpidemiologic MethodsKidney cancerBJU international
researchProduct

Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS

2005

Identification of major histocompatibility complex (MHC)-associated peptides recognized by T-lymphocytes is a crucial prerequisite for the detection and manipulation of specific immune responses in cancer, viral infections, and autoimmune diseases. Unfortunately immunogenic peptides are less abundant species present in highly complex mixtures of MHC-extracted material. Most peptide identification strategies use microcapillary LC coupled to nano-ESI MS/MS in a challenging on-line approach. Alternatively MALDI PSD analysis has been applied for this purpose. We report here on the first off-line combination of nanoscale (nano) LC and MALDI TOF/TOF MS/MS for the identification of naturally proce…

CellsCellPeptideHuman leukocyte antigenMajor histocompatibility complexSensitivity and SpecificityBiochemistryEpitopeAnalytical ChemistryMajor Histocompatibility ComplexImmune systemCell Line TumormedicineHumansAmino Acid SequenceCarcinoma Renal CellMolecular Biologychemistry.chemical_classificationbiologyHistocompatibility Antigens Class IFlow CytometryMolecular biologyKidney NeoplasmsPeptide FragmentsNeoplasm Proteinsmedicine.anatomical_structurechemistrySpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbiology.proteinTime-of-flight mass spectrometryAntibodyMolecular & Cellular Proteomics
researchProduct

Interleukins

1994

With interleukins (IL), a new class of potential drugs has been introduced into clinical research. These signal peptides are involved in the regulation of many physiological and pathophysiological processes. IL-1, -2, -3, -4, -6 and -11 have been tested in clinical trials. The growth promoting, growth inhibiting or immunomodulatory activities of interleukins represent the theoretical basis for large scale clinical testing, predominantly in malignant disease. Dose-dependent effects on numbers of peripheral blood cells and recovery from bone marrow failure have been demonstrated for IL-1, -3, -6 and -11. Phase III trials are in progress to determine their value for clinical practice. However,…

Clinical Trials as TopicClinical pharmacologybusiness.industryInterleukinsMelanomamedicine.medical_treatmentBone marrow failuremedicine.diseaseBioinformaticslaw.inventionClinical trialHaematopoiesisClinical researchCytokineAdjuvants ImmunologiclawRenal cell carcinomaNeoplasmsImmunologyAnimalsHumansMedicinePharmacology (medical)businessDrugs
researchProduct

Cytoplasmic microvesicles in chromophobe cell renal carcinoma demonstrated by freeze fracture

1987

In the chromophobe cell type of renal carcinoma, cytoplasmic microvesicles (frequently with "inner vesicles") demonstrable by transmission electron microscopy are one of the most important diagnostic features. The present paper reports on these microvesicles in freeze fracture replicas. Their diameter is mainly between 140 and 300 micron, but smaller and very much larger vesicles may also occur. The vesicle membrane is devoid of, or contains only scanty intramembranous particles. Cytoplasmic invaginations, probably the precursors of "inner vesicles" can also be detected. Connections with the agranular endoplasmic reticulum, mitochondria or other cell components could not be documented. Larg…

CytoplasmPathologymedicine.medical_specialtyKidneyVesicleCellChromophobe cellVacuoleBiologyMitochondrionKidney NeoplasmsMicrovesiclesmedicine.anatomical_structureCytoplasmmedicineFreeze FracturingHumansCarcinoma Renal CellVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-…

2000

The HER-2/neu oncoprotein, a 185 kDa membrane-associated tyrosine kinase with extensive homology to the epidermal growth factor receptor (EGF-R), is overexpressed in breast and ovarian carcinomas. Its overexpression is closely associated with poor prognosis in the course of disease. Here we demonstrate HER-2/neu overexpression in both established cell lines and biopsy material obtained from renal epithelial tumors. Immunohistochemical analysis of human kidney tumor lesions using 2 HER-2/neu-specific antibodies revealed HER-2/neu expression in more than 40% of primary epithelial renal tumors and more than 30% of primary renal cell carcinoma (RCC) specimens. A distinctive HER-2/neu expression…

Cytotoxicity ImmunologicCancer ResearchCellular immunityPathologymedicine.medical_specialtyReceptor ErbB-2BiologyEpitopeEpitopesAntigenRenal cell carcinomaAntigens NeoplasmHLA-A2 AntigenmedicineCytotoxic T cellHumansRNA MessengerRNA NeoplasmCarcinoma Renal CellNeoplasm StagingDendritic CellsGenes erbB-2medicine.diseaseKidney NeoplasmsPeptide FragmentsNeoplasm ProteinsCTL*OncologyCancer researchbiology.proteinImmunohistochemistryAntibodyT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma

2005

Renal cell carcinoma (RCC) representing the most common neoplasia of the kidney in Western countries is a histologic diverse disease with an often unpredictable course. The prognosis of RCC is worsened with the onset of metastasis, and the therapies currently available are of limited success for the treatment of metastatic RCC. Although gene expression analyses and other methods are promising tools clarifying and standardizing the pathological classification of RCC, novel innovative molecular markers for the diagnosis, prognosis, and for the monitoring of this disease during therapy as well as potential therapeutic targets are urgently needed. Using proteome-based strategies, a number of RC…

DiseaseBiologyFatty Acid-Binding ProteinsKidneyurologic and male genital diseasesmedicine.disease_causeBiochemistryMetastasisReference ValuesRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalUrotheliumCarcinoma Renal CellneoplasmsMolecular BiologyDNA PrimersKidneyReverse Transcriptase Polymerase Chain ReactionPrognosismedicine.diseaseImmunohistochemistryKidney Neoplasmsfemale genital diseases and pregnancy complicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureImmunologyDisease ProgressionCancer researchUrotheliumCarrier ProteinsCarcinogenesisKidney diseasePROTEOMICS
researchProduct

Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.

2022

Background: A subset of patients with metastatic renal cell carcinoma (mRCC), deemed as primary refractory, shows progressive disease as the best response to first-line therapy even when treated with novel immune-based combos. Objective: We aimed to assess the outcome of patients treated with second-line cabozantinib for mRCC primary refractory to first-line therapy defined as Response Evaluation Criteria in Solid Tumors (RECIST) progression in the computed tomography scan as the best response to the upfront treatment. Design, setting, and participants: We retrospectively collected data from 11 worldwide centers. Outcome measurements and statistical analysis: Overall survival (OS) and progr…

First lineSecond linePrimary refractorySettore MED/06 - Oncologia MedicaUrologyCabozantinibRenal cell carcinomaEuropean urology focus
researchProduct

Karyotype analysis and marker chromosomes of renal cell carcinoma.

1988

Karyotyping was performed in 46 human renal cell carcinomas of various histological grades. Controls included chromosome analysis of normal renal parenchymal cells from the same patients. Various numerical chromosome aberrations were found as well as marker chromosomes. They are specific of the individual tumor but no single marker was identified occurring in all tumors tested. Only trisomy 3 was found in different tumors (31%), suggesting a more general character of this aberration. Histological dedifferentiation and large tumor size correlate with focusing of the karyotype towards distinct chromosomal modes indicative of distinct tumor cell subclones within these tumors. Their rapid growt…

Genetic MarkersPathologymedicine.medical_specialtyPoor prognosisbusiness.industryUrologyCellChromosomeKaryotypeTrisomymedicine.diseaseKidneyKidney Neoplasmsmedicine.anatomical_structureChromosome 3Renal cell carcinomaKaryotypingParenchymamedicineHumansRing ChromosomesHistological gradesChromosomes Human Pair 3businessCarcinoma Renal CellEuropean urology
researchProduct